<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383383</url>
  </required_header>
  <id_info>
    <org_study_id>208129/042</org_study_id>
    <nct_id>NCT00383383</nct_id>
  </id_info>
  <brief_title>Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years</brief_title>
  <official_title>To Compare the Immunogenicity &amp; Safety of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B, in Pre-Haemodialysis/Haemodialysis Patients (≥15 Years of Age)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Comparison of adjuvanted hepatitis B vaccine to double dose of Engerix™-B in pre-
      /haemodialysis patients aged ≥15 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HBs seroprotection rates at Month 12.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited symptoms, unsolicited symptoms and serious adverse events</measure>
  </secondary_outcome>
  <enrollment>141</enrollment>
  <condition>Hepatitis B</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B adjuvanted vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female &gt; = 15 years of age at the time of the first vaccination.

          -  Written informed consent obtained from the subject/ from the parents or guardians of
             the subject.

          -  Seronegative for anti-HBs antibodies, anti-HBc antibodies &amp; Hepatitis B Surface
             antigen (HBsAg).

          -  If the subject was a female, she was of non-childbearing potential or, if of
             childbearing potential, she had to be abstinent or use adequate contraceptive
             precautions for one month prior to enrollment and up to two months after the last
             vaccination.

          -  Pre-haemodialysis patient* or a patient on haemodialysis.

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine during the study period or within 30 days preceding the first dose of study
             vaccine.

          -  Previous vaccination against hepatitis B.

          -  History of hepatitis B infection.

          -  Known exposure to hepatitis B virus within 6 weeks. Pregnant or lactating female

          -  Clinically abnormal ALT/AST values (&gt; 3 times normal values)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Hradec</city>
        <state>Králové</state>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Malaysia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <last_update_submitted>October 2, 2006</last_update_submitted>
  <last_update_submitted_qc>October 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

